Genfit SA
(NASDAQ : GNFT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.41%430.050.0%$6120.58m
BNTXBioNTech SE -3.62%359.180.0%$1251.77m
NVAXNovavax, Inc. 0.11%237.5479.4%$944.01m
SNSSSunesis Pharmaceuticals, Inc. 2.23%8.710.7%$608.86m
AMGNAmgen, Inc. 0.93%219.381.4%$559.38m
REGNRegeneron Pharmaceuticals, Inc. -0.20%651.882.7%$494.43m
GILDGilead Sciences, Inc. 0.39%71.611.0%$434.34m
ILMNIllumina, Inc. -0.65%447.013.5%$405.38m
TECHBio-Techne Corp. 0.92%534.354.5%$355.95m
BIIBBiogen, Inc. 0.17%300.191.7%$306.30m
VRTXVertex Pharmaceuticals, Inc. 0.64%188.301.9%$241.59m
ISEEIVERIC bio, Inc. 1.59%16.620.0%$194.78m
BGNEBeiGene Ltd. 4.65%403.141.3%$186.17m
LIFEaTyr Pharma, Inc. 0.49%10.313.2%$144.19m
EXASEXACT Sciences Corp. 5.22%108.1518.1%$135.69m

Company Profile

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.